Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems

Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic, and consumer health products, today announced that Dr. Jeff Browne, R&D Director and US Platform Leader of Pharmaceutical Softgels, will present “Enhancing the Bioavailability of Absorption-Limited Drugs with Lipid-Based Formulations using Soft Capsule Delivery Systems” at the forthcoming 30th Annual Meeting of the Japan Society of Drug Delivery Systems (30-31 July 2014, Tokyo, Japan).

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Somerset, NJ (PRWEB) July 29, 2014

Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic, and consumer health products, today announced that Dr. Jeff Browne, R&D Director and US Platform Leader of Pharmaceutical Softgels, will present “Enhancing the Bioavailability of Absorption-Limited Drugs with Lipid-Based Formulations using Soft Capsule Delivery Systems” at the forthcoming 30th Annual Meeting of the Japan Society of Drug Delivery Systems (30-31 July 2014, Tokyo, Japan).

Dr. Browne’s presentation, which is a luncheon seminar on Wednesday July 30th, at 12.00 noon, will provide insight into the usefulness of lipid-based formulations to enhance absorption for drugs with limited oral bioavailability, characterized by poor solubility and/or permeability. The process of preformulation studies and prototype formulation development on a placebo lipid-based formulation will be used to demonstrate the considerations necessary before highlighting the benefits of soft capsules as a delivery method for such formulations. Catalent’s non-gelatin OptiShell™ capsule technology has successfully been used to overcome incompatibilities with gelatin-based shells, and more recently, the use of film-coated soft capsules has been investigated.

Dr. Browne’s career with Catalent started in 1994 and since then, he has held a number of positions before becoming R&D Director and US Platform Leader of Pharma Softgels. These included Executive Director & Division Head of Pharmaceutical Development in Research Triangle Park, NC, and most recently Technical Director, Pharmaceutical Softgels. He is an active member of the American Association of Pharmaceutical Scientists (AAPS) and has served on several of their Focus Group committees. He is a frequent presenter at both regional and national AAPS meetings. Dr. Browne received his Ph.D. from Purdue University in Industrial and Physical Pharmacy.

For more information on the Japan Society of Drug Delivery Systems, visit: http://www.procomu.jp/DDS2014/index.html, and to arrange a meeting with Dr. Browne, contact Richard Kerns at richard(at)nepr(dot)eu.

About Catalent:

Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents, and in Fiscal 2013, generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™


Contact

  • Richard Kerns
    Northern Exposure PR
    +44 (0) 7974 579202
    Email